首页> 外文期刊>Therapeutic Drug Monitoring >Therapeutic Drug Monitoring in Pregnant Patients
【24h】

Therapeutic Drug Monitoring in Pregnant Patients

机译:孕妇治疗药物监测

获取原文
获取原文并翻译 | 示例
       

摘要

During pregnancy, there are several physiological changes during each trimester that can affect the absorption, distribution, metabolism, and elimination of drugs. Although there is a potential need to understand the pharmacokinetics and pharmacodynamics of drugs in pregnant patients, therapeutic drug monitoring is not well established for various drug classes due to ethical and safety concerns regarding the neonate. Potential risks from in utero drug exposure to the fetus may impact growth and development and may cause malformations or teratogenesis. The clinician must consider the benefits of drug treatment for the pregnant mother versus the risk to the fetus, before prescribing medications during pregnancy. The objective of this review is to aid clinicians, pharmacists, and laboratorians in understanding the pharmacokinetic and pharmacodynamic changes during pregnancy, to provide drug class recommendations for monitoring therapy throughout pregnancy via therapeutic drug monitoring, and to highlight the recent directives of governing agencies on maternal and fetal health.
机译:在怀孕期间,每个三月期间有几种生理变化,可能会影响吸收,分布,新陈代谢和消除药物。虽然潜在需要了解孕妇药代动力学和药物动力学,但由于关于新生儿的道德和安全问题,各种药物课程对治疗药物监测不充分建立。从子宫药物暴露于胎儿的潜在风险可能会影响生长和发展,可能导致畸形或畸胎发生。临床医生必须考虑怀孕母亲对孕妇的益处与胎儿的风险,在怀孕期间的药物之前。本综述的目的是帮助临床医生,药剂师和实验室了解怀孕期间的药代动力学和药物动力学变化,以通过治疗药物监测提供治疗治疗的药物课程建议,并突出近期孕产事件的近期指令和胎儿健康。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号